MedDataX Logo

Group Telehealth Behavioral Cough Suppression Therapy

NCT ID: NCT06706765

Last Updated: 2024-11-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

EARLY_PHASE1

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-22

Study Completion Date

2025-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the effectiveness of behavioral cough suppression therapy (BCST) in managing refractory chronic cough (RCC) within a group telehealth setting. RCC is a cough that has lasted at least 8 weeks and has not resolved with standard medical treatment. BCST is a research-based treatment provided by specialty-trained speech-language pathologists (SLPs) for patients with RCC. Although the treatment works very well for a large proportion of patients in a standard one-on-one format, there are a limited number of SLPs available to provide this treatment and patients living in rural areas do not typically have access to an SLP trained in BCST. If BCST can effectively be delivered in a group telehealth model, it would significantly improve accessibility to the treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Refractory Chronic Cough

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group Telehealth Behavioral Cough Suppression Therapy

Group Type EXPERIMENTAL

Behavioral Treatment

Intervention Type BEHAVIORAL

Behavioral cough suppression therapy delivered in a group setting via telehealth.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Behavioral Treatment

Behavioral cough suppression therapy delivered in a group setting via telehealth.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* At least 18 years old
* Predominantly dry cough for at least 8 weeks
* Evaluated and treated by at least one physician for cough
* Obtained a chest X-ray or chest CT scan specifically related to the cough with unremarkable results
* Access to a computer or tablet that includes a camera and able to use the device independently
* Reliable internet access
* Willing to agree to maintain confidentiality of personal information (including names) related to others in the study

Exclusion Criteria

* Under age 18
* Coughing up blood
* Current smoker of any substance
* History of smoking or 10 or more years
* Diagnosed with a chronic lung condition (e.g., COPD, emphysema, lung cancer, idiopathic pulmonary fibrosis, chronic bronchitis, asthma)? (NOTE: If a patient has been told their cough may be (or is likely) due to asthma but they have not had any formal lung testing and asthma treatments have not helped your cough, we don't consider this a formal asthma diagnosis and will not exclude them from the study.)
* Diagnosed currently or in the past with head and neck cancer (i.e., cancer of the mouth, nose, or throat).
* Complaints of swallowing difficulty
* Taking any of the following medications, which have a known side effect of cough: Benzapril (Lotensin), Captopril (Capoten), Enalapril/Enalaprilat (Vasotec oral and injectable), Fosinopril (Monopril), Lisinopril (Zestril and Prinivil), Moexipril (Univasc), Perindopril (Aceon), Quinapril (Accupril), Ramipril (Altace), and Trandolapril (Mavik)
* Prior BCST treatment with an SLP or respiratory therapist
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Montana

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Montana

Missoula, Montana, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jane E Reynolds, PhD

Role: CONTACT

[email protected]
406-243-2138

Laurie J Slovarp, PhD

Role: CONTACT

[email protected]
406-243-2107

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jane E Reynolds, PhD

Role: primary

[email protected]
406-243-2138

Laurie J Slovarp, PhD

Role: backup

[email protected]
406-243-2107

Laurie J Slovarp, PhD

Role: backup

Jane E Reynolds, PhD

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB-FY2024-36

Identifier Type: -

Identifier Source: org_study_id